Connect with us

News

Advances in gynaecological cancer research could change the treatment landscape, say researchers

Novel findings on gynaecological cancers will be revealed later this month at the ESMO Congress 2023 in Madrid

Published

on

Advances in gynaecological cancer research could change the treatment landscape, researchers have said, allowing women struggling with these cancers to live longer.

Results from highly anticipated clinical trials in gynaecological cancers with, among others, new data that cover the entire spectrum of managing patients with cervical cancer, will be presented at the ESMO Congress 2023 in Madrid, Spain.

These studies, researchers say, could change the treatment landscape for women with these cancers, delaying the time to relapse and, in some cases, lengthening survival.

“These are exciting results that address unmet needs in gynaecological cancers,” says Professor Krishnansu S. Tewari, director of the Gynecologic Oncology Programme, University of California, Irvine.

Novel findings will be revealed at the congress across the range of gynaecological cancers, including cervical, ovarian, and endometrial cancers.

Cervical cancer usually presents as locally advanced disease in women who have not undergone screening. At this stage, the cancer is too large to remove surgically, and the standard treatment is chemotherapy with radiation.

“Cervical cancer occurs in young women who are typically in the midst of their careers and have small children at home,” explains Tewari.

“Standard treatment does lead to remission, but within two to three years the cancer can come back. Two trials that will be presented at the ESMO Congress 2023 will reveal new ways of treating locally advanced cervical cancer that significantly delay relapse, giving women who are in the prime of their lives more time free of cancer.”

In one study, 68 per cent of women who received the immunotherapy drug pembrolizumab on top of standard treatment were cancer-free at two years, compared to 57 per cent of women allocated to placebo on top of standard treatment.

A second study tested the impact of giving a combination of two different chemotherapy drugs ahead of standard treatment with chemotherapy plus radiation, a strategy called induction chemotherapy.

Women with locally advanced cervical cancer who received induction chemotherapy were 35 per cent more likely to be cancer-free at five years and 39 per cent more likely to be alive at five years compared to those who received standard treatment only.

Tewari says: “Induction chemotherapy could be an accessible treatment option because these drugs are available around the world, including in low-resource countries.”

Also in cervical cancer, trials will be presented showing improvements in survival and delays in relapse with new treatments for women with cancer that has spread to other parts of the body or has come back after being treated.

In ovarian cancer, achieving remission is a high unmet need, say scientists, as approximately 85 per cent of patients experience recurrent disease, with almost no long-term survival after recurrence.

At the ESMO Congress 2023, randomised trial data will be discussed showing that a novel targeted therapy, called senaparib, could delay the time to relapse in patients with newly diagnosed advanced disease.

Studies will also be presented in endometrial cancer, the most common gynaecological cancer in the US and Europe.

While there is no screening test for endometrial cancer, there is an early symptom, post-menopausal bleeding, which means that most endometrial cancers can be cured with a hysterectomy.

“Unfortunately, for the 15-20 per cent of patients that have more aggressive disease, treatment options are very limited and that’s why the studies that will be presented at the ESMO Congress are remarkable,” says Professor Tewari.

“Two trials showed that adding immunotherapy to standard chemotherapy treatment significantly delayed relapse of the cancer in women with advanced/recurrent endometrial cancer compared to chemotherapy alone.”

The researcher thinks the results that will be presented at the ESMO Congress 2023 have a very good chance of leading to regulatory approval of new treatments.

He says: “These trials have set the stage for women with gynaecological cancers to receive state-of-the-art therapies that delay the time to relapse, allowing women struggling with these cancers to live longer and live better.”

Fertility

Fertility clinic named London finalist in UK StartUp Awards

Published

on

A London-based fertility clinic has been shortlisted for a startup award.

Plan Your Baby was shortlisted as a London finalist for Innovative Startup of the Year at the UK StartUp Awards.

Plan Your Baby is a new generation fertility and pregnancy telehealth clinic that provides fertility treatment and and-to-end pregnancy clinical monitoring and psychological support.

The company said on LinkedIn: “Being recognised in a city as competitive as London is meaningful for our team. 

“The award is judged by industry experts and reflects the growing need for fertility care that is structured, transparent, and centred around the patient.

“Many people come to us looking for clarity in what can often feel like a complex process. 

“Our focus has been to make each step easier to understand and easier to access.”

Plan Your Baby founder Marija Skujina was inspired to launch the company after working at the highest level in private fertility clinics and realising the impact that the traditional approach to fertility treatment was having on clients.

She told Femtech World in a 2023 interview: ““Fertility support is not just a medical procedure, it’s physical, mental, and emotional too.

“That’s why I launched Plan Your Baby: to help parents conceive in a fully supported and holistic manner.”

The UK StartUp Awards aim to ‘recognise the achievements of amazing individuals who have had a great idea, spotted the opportunity and taken the risks to launch a new product or service.’

If selected as the regional winner, Plan Your Baby will go on to the national final at Ideas Fest this September.

Previous winners include Magic AI, makers of a wall-mounted AI fitness mirror that acts as a personal trainer, and EnsiliTech, a medtech startup developing innovative health technology solutions at the intersection of engineering and healthcare.

Continue Reading

News

What 100k+ journalled words reveal about women’s mental load

Published

on

By Katrina Zalcmane, co-founder of Véa

101,000 journalled words. That’s what it took to make women’s mental load measurable – and what it revealed was not what we expected.

We can track a woman’s cycle to the hour, map her hormones, her fertility window, her sleep habits.

But we have had remarkably little structured visibility into the cognitive and emotional load running underneath all of it – the layer that shapes how she makes decisions, takes risks, recovers from pressure and moves through her day.

That’s where the data gets interesting.

Across those 101,000 anonymously journalled words, Véa identified the cognitive signatures of how pressure gets metabolised – not into symptoms, but into patterns.

Overgeneralisation, fortune-telling, catastrophising: the interpretive architecture through which strain quietly becomes self-doubt, avoidance and reduced capacity.

This is not a wellness story – it’s a data story. And it points to a layer of women’s health that has been consistently underinstrumented.

Véa is an neuroscience-backed AI journal that uses semantic embeddings and a state classifier trained on emotional data to read language the way a clinician might – not for keywords but for interpretive patterns.

Each entry is stored as an emotional vector, building a longitudinal map of how a user’s inner state shifts over time.

That is what made this dataset possible.

What the Data Shows

Mental load is often described in domestic terms – the remembering, the planning, the anticipating. But in practice it is also deeply interpretive.

It lives in the ongoing internal work of pre-empting what might go wrong, reading emotional atmospheres, managing self-presentation and correcting internally before anything external has even happened.

That is not just emotional strain. It is a form of continuous cognitive expenditure.

To make that visible, Véa analysed 101,000 anonymously journalled words across 150+ beta testers over 6 months.

These were not a homogenous group: new mothers, neurodivergent women, career-switchers, high performers navigating demanding roles – different lives, different pressures, same underlying patterns.

That breadth matters – it means what we found is not a niche signal. It is structural.

Across that dataset, Véa identified more than 3,000 separate instances of cognitive distortions – recurring interpretive patterns that emerge under pressure.

The five most frequently detected were overgeneralisation, fortune-telling, “should” statements, catastrophising and black-and-white thinking.

On paper these may sound like standard CBT terminology. But taken together they reveal something more significant than stress.

They show that a large part of women’s mental and emotional load is not only what women are carrying externally – it is how rapidly and repeatedly that load gets cognitively organised into threat, failure and self-correction.

What drains women is not just the event. It is the meaning-making around the event.

The Cost of Cognitive Distortions

Overgeneralisation: when one setback becomes a self-story

The most frequent pattern was overgeneralisation: turning one event into a broader conclusion.

One awkward meeting becomes “I’m not good enough”. One rejection becomes “this always happens to me”.

Under stress, the prefrontal cortex loses flexibility, making it harder to hold context and alternative interpretations.

The brain defaults to faster, simplified conclusions, often collapsing a single event into a broader narrative.

For high-performing women, this matters because it directly affects risk-taking and recovery. If one setback becomes a signal of incompetence, the cost of visibility increases.

This aligns with workplace data showing women are more likely to self-deselect from opportunities after negative feedback or perceived underperformance.

Overgeneralisation is not just negative thinking. It is a reduction in cognitive flexibility that limits forward movement.

Fortune-telling: managing problems before they exist

The second pattern was: predicting negative outcomes without evidence, e.g. “It’s going to go badly” or “They’re not going to respond” when you have no facts to back that up.

The brain operates on predictive models, continuously forecasting outcomes.

Under stress, these predictions become threat-biased and less accurate, prioritising avoidance over exploration.

For women, this overlaps with documented anticipatory mental load – the cognitive work of planning, monitoring and pre-empting problems.

The result is inefficiency: energy is spent solving for outcomes that have not occurred.

For high performers, this reduces focus, presence and execution quality because attention is allocated to imagined scenarios rather than current tasks.

“Should” statements: the language of self-surveillance

“Should” statements reflect top-down self-monitoring where behaviour is continuously evaluated against internalised standards. Under sustained pressure, this shifts from regulation to self-criticism, increasing cognitive load.

For women, these standards are often compounded. Performance, emotional regulation and relational behaviour are all being evaluated simultaneously.

Workplace data shows women face higher expectations to balance competence with likability and are more likely to experience competence-based microaggressions.

This creates a loop of self-surveillance, splitting attention between doing and evaluating.

That split is cognitively expensive.

Catastrophising: when the system defaults to threat

Catastrophising reflects rapid escalation to worst-case scenarios.

Under cognitive load, the brain shifts toward amygdala-driven threat processing, reducing the ability to hold ambiguity and increasing urgency-based interpretation.

For high-performing women managing multiple demands, even small uncertainties can trigger escalation because they are processed on top of existing load.

The outcome is distorted prioritisation. Attention is redirected toward perceived threats rather than actual strategic work.

Black-and-white thinking: the rigidity behind perfection

The final major pattern was black-and-white thinking: interpreting situations in binaries, e.g “I’m either doing well or failing”.

It reflects reduced cognitive flexibility, a key function of the prefrontal cortex that allows for nuance and adaptive thinking.

It makes recovery harder and leaves very little room for partial progress, mixed feelings or ordinary human inconsistency.

For high-performing women, this often intersects with perfection pressure. Partial progress is discounted and anything below optimal performance is interpreted as failure.

This creates rigidity. It limits iteration, slows decision-making and makes sustained performance harder, not better.

What This Actually Means

Clinical surveys can tell you a woman is stressed. Journalling treated as longitudinal data tells you something different – it shows you how that stress is being interpreted, repeated and compounded over time.

A survey captures a moment. Language tracked across weeks and months captures a pattern.

That distinction is what makes this dataset structurally different from existing research: it surfaces the cognitive layer that self-report instruments are not designed to reach.

For corporate health and wellbeing

These patterns do not stay at home.

Overgeneralisation after a difficult meeting, fortune-telling before a high-stakes presentation, black-and-white thinking under performance pressure – these are showing up in the workplace every day, invisibly.

For organisations investing in women’s development and retention, this data reframes the conversation.

It is not enough to offer resilience training or mental health days.

The question is whether your wellbeing infrastructure is designed to address the interpretive load that sits underneath performance and whether the interventions you offer are actually built around how women experience that load.

Because that is where capacity is actually being lost.

For clinical and health frameworks

The most widely used depression screener in the world is nine questions long. It captures a snapshot.

What longitudinal language data offers is something clinical instruments have never been designed to provide – continuity.

A running record of how cognitive patterns shift, accumulate and respond to pressure over time, before they become a diagnosis.

That has real implications for how we screen, how we intervene early and how we build a picture of women’s mental health that goes beyond the biological and into the cognitive.

Continue Reading

Entrepreneur

Women’s Health Week USA confirms full speaker lineup and records 170 pitch applications

Published

on

By Women’s Health Week

With four weeks to go until Women’s Health Week USA, the excitement is ramping up!

The final early bird pricing closes this Friday, the full speaker lineup is confirmed, and a record number of pitch applications signals the depth of innovation now moving through the sector as we enter the Era of Scale.

Women’s Health Week USA takes place May 13-14 at the New York Academy of Medicine in New York City, bringing together 600+ senior decision makers spanning investors, founders, multinationals, payers, providers and policymakers around one shared agenda: taking women’s health from growth to scale.

Early bird tickets are available until midnight on Friday, April 17.

Book by then to save up to $600 on your place

The Full Speaker Lineup is Confirmed

The full speaker lineup has finally been confirmed, with 80+ voices spanning investment, innovation, policy, medtech and pharma.

The programme reflects the event’s 2026 theme, The Era of Scale, moving beyond early validation into the harder work of institutionalising women’s health as a category.

Confirmed speakers include Kate Ryder (Maven Clinic), Mallika Mundkur (FDA), Melanie Newman (Planned Parenthood), Nichole Young-Lin (Google), Jill Angelo (OURA), David Stern (Kindbody) and Tammy Sun (Carrot Fertility), alongside representation from the NYSE, ARPA-H, the World Health Organization, Samsung Next, Novo Holdings and more.

View the full speaker lineup

170 Pitch Applications and Counting

The Women’s Health Week USA Innovation Showcase received a record 170 applications ahead of its April 10 close, the highest number in the event’s history.

The volume reflects the growing depth of innovation in the sector, but it was the quality of submissions that stood out, with companies across Medical Devices & Therapeutics and Consumer & Tech bringing genuinely differentiated solutions to conditions that have been underserved for decades.

The selected companies will get the chance to pitch on the mainstage at the New York Academy of Medicine in front of the full audience of 600+ investors, corporates, innovators and strategic partners.

Results will be announced next week.

Register your interest to find out who makes the WHW USA Innovator Class of 2026

NYSE Partnership: A Quick Recap

For those who missed our announcement on Femtech World last week, the New York Stock Exchange is the Official Exchange Partner of Women’s Health Week USA 2026.

On the morning of May 13, WHW will feature in the NYSE Market Update, reaching approximately 200 million viewers.

Women’s Health Week will also light up the North Star Billboard in Times Square for a full week around the event, with live and taped interviews distributed across NYSE Live and Taking Stock.

It remains one of the most significant institutional endorsements the women’s health sector has seen.

Early Bird Pricing Closes This Friday

Tickets increase by up to $600 after midnight on Friday, April 17. For anyone with May 13-14 in their calendar, this week is the window to move.

Download the full programme

Register before Friday

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.